Department of Psychiatry, School of Medicine, Vanderbilt University, Nashville, TN, USA; Tennessee Valley VA Healthcare System, Nashville Campus, Nashville, TN, USA.
Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Psychiatry Res. 2015 Mar 30;226(1):308-15. doi: 10.1016/j.psychres.2015.01.007. Epub 2015 Jan 15.
Serotonin (5-HT)2C receptors in brain affect psychosis, reward, substance abuse, anxiety, other behaviors, appetite, body temperature, and other physiological measures. They also have been implicated in antipsychotic drug efficacy and side effects. We previously reported that the hyperthermia following administration of MK-212, a predominantly 5-HT(2C) receptor agonist, was diminished in a small sample of patients with schizophrenia (SCH), suggesting decreased 5-HT(2C) receptor responsiveness. We have now studied the responses to oral MK-212 and placebo in a larger sample of unmedicated male SCH (n = 69) and normal controls (CON) (n = 33), and assessed the influence of comorbid substance abuse (SA) on oral body temperature, behavioral responses, etc. The placebo-adjusted oral body temperature response to MK-212 was significantly lower in SCH compared to CON and not significantly different between the SCH with or without SA. Some behavioral responses to MK-212, e.g. self-rated feelings of increased anxiety, depression and decreased calmness, or good overall feeling, were significantly lower in the SCH patients compared to CON. These results add to the evidence for diminished 5-HT(2C) receptor responsiveness in SCH patients compared to CON and are consistent with reported association of HTR(2C) polymorphisms, leading to decreased expression or function of the HTR(2C) in patients with SCH.
脑内的血清素(5-HT)2C 受体影响精神分裂症、奖励、药物滥用、焦虑、其他行为、食欲、体温和其他生理指标。它们也与抗精神病药物的疗效和副作用有关。我们之前报道过,MK-212(一种主要的 5-HT(2C)受体激动剂)给药后引起的发热在一小部分精神分裂症(SCH)患者中减少,这表明 5-HT(2C)受体反应性降低。我们现在在更大的未用药的男性 SCH(n = 69)和正常对照组(CON)(n = 33)样本中研究了口服 MK-212 和安慰剂的反应,并评估了合并物质滥用(SA)对口服体温、行为反应等的影响。与 CON 相比,SCH 患者口服 MK-212 后的安慰剂调整后的体温反应显著降低,且与 SCH 患者是否合并 SA 无关。与 CON 相比,SCH 患者对 MK-212 的一些行为反应,如自我评估的焦虑、抑郁和冷静感降低,或整体感觉良好,明显降低。这些结果增加了与 SCH 患者相比,CON 患者 5-HT(2C)受体反应性降低的证据,并且与 HTR(2C)多态性的报道相关,导致 SCH 患者 HTR(2C)的表达或功能降低。